JP7699836B2 - Ｋｃｎｔ１阻害剤、および使用方法 - Google Patents
Ｋｃｎｔ１阻害剤、および使用方法 Download PDFInfo
- Publication number
- JP7699836B2 JP7699836B2 JP2022551290A JP2022551290A JP7699836B2 JP 7699836 B2 JP7699836 B2 JP 7699836B2 JP 2022551290 A JP2022551290 A JP 2022551290A JP 2022551290 A JP2022551290 A JP 2022551290A JP 7699836 B2 JP7699836 B2 JP 7699836B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- epilepsy
- compound
- mmol
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982804P | 2020-02-28 | 2020-02-28 | |
| US202062982830P | 2020-02-28 | 2020-02-28 | |
| US202062982838P | 2020-02-28 | 2020-02-28 | |
| US62/982,830 | 2020-02-28 | ||
| US62/982,804 | 2020-02-28 | ||
| US62/982,838 | 2020-02-28 | ||
| PCT/US2021/019814 WO2021173930A1 (en) | 2020-02-28 | 2021-02-26 | Kcnt1 inhibitors and methods of use |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023515576A JP2023515576A (ja) | 2023-04-13 |
| JP2023515576A5 JP2023515576A5 (https=) | 2024-03-04 |
| JPWO2021173930A5 JPWO2021173930A5 (https=) | 2024-03-04 |
| JP7699836B2 true JP7699836B2 (ja) | 2025-06-30 |
Family
ID=77492026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551290A Active JP7699836B2 (ja) | 2020-02-28 | 2021-02-26 | Ｋｃｎｔ１阻害剤、および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12583849B2 (https=) |
| EP (2) | EP4110317B1 (https=) |
| JP (1) | JP7699836B2 (https=) |
| KR (1) | KR20230005813A (https=) |
| CN (1) | CN115443129A (https=) |
| BR (1) | BR112022017191A2 (https=) |
| CA (1) | CA3169779A1 (https=) |
| IL (1) | IL295940A (https=) |
| MX (1) | MX2022010625A (https=) |
| WO (1) | WO2021173930A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250172745A (ko) * | 2019-05-03 | 2025-12-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| KR20220016086A (ko) * | 2019-05-03 | 2022-02-08 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| EP4329735B1 (en) * | 2021-04-29 | 2026-02-25 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003084948A1 (en) | 2002-03-14 | 2003-10-16 | Eisai Co., Ltd. | Nitrogenous heterocyclic compound and medicine thereof |
| JP2007532676A (ja) | 2004-04-13 | 2007-11-15 | イカジェン インコーポレイテッド | カリウムイオンチャネル調節剤としての多環式ピリジン |
| JP2017509682A (ja) | 2014-04-04 | 2017-04-06 | イオメット ファーマ リミテッド | 医療で使用されるインドール誘導体 |
| JP2022531388A (ja) | 2019-05-03 | 2022-07-06 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤および使用する方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE19929076A1 (de) | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| GB0127547D0 (en) | 2001-11-16 | 2002-01-09 | Astrazeneca Ab | Chemical compounds |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| JP2005060255A (ja) | 2003-08-20 | 2005-03-10 | Nippon Nohyaku Co Ltd | カルボキサミド類及びこれを有効成分とする有害生物防除剤 |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP2044061A2 (en) | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| US20080269241A1 (en) | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US8445686B2 (en) * | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| TW201642855A (zh) | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| EP3275440B1 (en) | 2015-03-25 | 2022-05-04 | National Center for Geriatrics and Gerontology | Novel oxadiazole derivative and pharmaceutical containing same |
| JPWO2017170826A1 (ja) | 2016-03-30 | 2019-02-14 | 味の素株式会社 | グルカゴン様ペプチド−１受容体作用増強活性を有する化合物 |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| CN114364693A (zh) | 2019-05-03 | 2022-04-15 | 新加坡保健服务私人有限公司 | 代谢性疾病的治疗和预防 |
| KR20250172745A (ko) | 2019-05-03 | 2025-12-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| KR20230005168A (ko) | 2020-03-23 | 2023-01-09 | 프락시스 프리시젼 메디신즈, 인크. | Kcnt1 억제제 및 사용 방법 |
| CA3188825A1 (en) | 2020-07-06 | 2022-01-13 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| US11773088B2 (en) | 2020-11-02 | 2023-10-03 | Praxis Precision Medicines, Inc. | KCNT1 inhibitors and methods of use |
| WO2022140547A2 (en) | 2020-12-22 | 2022-06-30 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| EP4329735B1 (en) | 2021-04-29 | 2026-02-25 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| US20250360117A1 (en) | 2022-06-08 | 2025-11-27 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors comprising an isoxazole or oxadiazole core and methods of use |
-
2021
- 2021-02-26 JP JP2022551290A patent/JP7699836B2/ja active Active
- 2021-02-26 EP EP21760026.1A patent/EP4110317B1/en active Active
- 2021-02-26 WO PCT/US2021/019814 patent/WO2021173930A1/en not_active Ceased
- 2021-02-26 BR BR112022017191A patent/BR112022017191A2/pt unknown
- 2021-02-26 EP EP25207650.0A patent/EP4692069A3/en active Pending
- 2021-02-26 MX MX2022010625A patent/MX2022010625A/es unknown
- 2021-02-26 US US17/904,963 patent/US12583849B2/en active Active
- 2021-02-26 CN CN202180028764.XA patent/CN115443129A/zh active Pending
- 2021-02-26 KR KR1020227033876A patent/KR20230005813A/ko active Pending
- 2021-02-26 IL IL295940A patent/IL295940A/en unknown
- 2021-02-26 CA CA3169779A patent/CA3169779A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003084948A1 (en) | 2002-03-14 | 2003-10-16 | Eisai Co., Ltd. | Nitrogenous heterocyclic compound and medicine thereof |
| JP2007532676A (ja) | 2004-04-13 | 2007-11-15 | イカジェン インコーポレイテッド | カリウムイオンチャネル調節剤としての多環式ピリジン |
| JP2017509682A (ja) | 2014-04-04 | 2017-04-06 | イオメット ファーマ リミテッド | 医療で使用されるインドール誘導体 |
| JP2022531388A (ja) | 2019-05-03 | 2022-07-06 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１阻害剤および使用する方法 |
Non-Patent Citations (4)
| Title |
|---|
| ChemistrySelect，2018年，Vol. 3, No. 39，p. 10996-10998 |
| PubChem [online]，2010年06月22日，[検索日 2025.01.14]，PubChem CID 46128945 |
| PubChem [online]，2015年12月10日，[検索日 2025.01.14]，PubChem CID 93117409 |
| REGISTRY（STN）[online]，2017年05月02日，[検索日 2024.11.19]，CAS登録番号 2094817-09-9, 2395549-12-7, 1832156-07-6 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115443129A (zh) | 2022-12-06 |
| BR112022017191A2 (pt) | 2022-11-08 |
| WO2021173930A1 (en) | 2021-09-02 |
| AU2021227935A1 (en) | 2022-09-22 |
| EP4110317A1 (en) | 2023-01-04 |
| EP4110317B1 (en) | 2025-11-19 |
| US12583849B2 (en) | 2026-03-24 |
| US20230167102A1 (en) | 2023-06-01 |
| CA3169779A1 (en) | 2021-09-02 |
| IL295940A (en) | 2022-10-01 |
| EP4692069A3 (en) | 2026-04-08 |
| JP2023515576A (ja) | 2023-04-13 |
| MX2022010625A (es) | 2022-10-27 |
| KR20230005813A (ko) | 2023-01-10 |
| EP4110317A4 (en) | 2024-02-28 |
| EP4692069A2 (en) | 2026-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7699836B2 (ja) | Ｋｃｎｔ１阻害剤、および使用方法 | |
| JP7667573B2 (ja) | Ｋｃｎｔ１阻害剤および使用する方法 | |
| JP7671990B2 (ja) | Ｋｃｎｔ１阻害剤および使用する方法 | |
| EP2917206B1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| JP7838820B2 (ja) | Ｋｃｎｔ１阻害剤及び使用方法 | |
| JP4576386B2 (ja) | アルツハイマー病治療用のベンジルエーテルおよびベンジルアミノ系β−セクレターゼ阻害薬 | |
| EP3704118B1 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| US11851428B2 (en) | Activator of TREK (TWIK RElated K+channels) channels | |
| JP7824664B2 (ja) | Ｋｃｎｔ１阻害剤及び使用方法 | |
| AU2004311749A1 (en) | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| CA3112735A1 (en) | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) | |
| EP4329735B1 (en) | Kcnt1 inhibitors and methods of use | |
| US20240043415A1 (en) | Kcnt1 inhibitors and methods of use | |
| WO2024173291A1 (en) | Compounds and compositions as stat3 degraders and uses thereof | |
| AU2021227935B2 (en) | KCNT1 inhibitors and methods of use | |
| EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240222 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240222 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250411 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250520 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250611 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7699836 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |